Big Health acquires prescription PDT company Limbix

Digital therapeutics company Big Health, has recently completed the acquisition of Limbix, a renowned developer of prescription digital therapeutics designed to tackle depression among teenagers and young adults. Limbix is widely recognized as the creator of SparkRx, a PDT solution that utilises cognitive behavioural therapy principles to address depression specifically in individuals aged 13 to 22.

SparkRx, a self-guided treatment based on CBT, was initially launched in October 2021. This launch coincided with the FDA's more relaxed regulatory requirements for digital health devices intended to treat psychiatric disorders during the pandemic.

With this acquisition, SparkRx will become part of Big Health's comprehensive portfolio, which already includes Daylight, a therapeutic solution for anxiety, and Sleepio, a platform dedicated to insomnia treatment.

In a statement, Ben Lewis, the cofounder and CEO of Limbix, expressed his enthusiasm for the alignment between Limbix and Big Health. He highlighted their shared commitment to providing primary digital therapeutics for a wide range of mental health conditions. Lewis further explained that as the industry leader, Big Health serves as a natural fit for SparkRx, Limbix's upcoming product pipeline, and their team. By joining forces, they aim to accelerate the provision of effective, clinically-proven digital depression treatments to young people, equipping them with tools for meaningful improvement in their mental well-being.

Click here to read the original news story.